Fig. 4

Efficacy of apatinib and afatinib in PDX models. a Therapeutic response of apatinib with expressions of CD31 and corresponding tumor volumes before and after treatment (n = 5 per group). Tumor volumes were expressed as means ± SD. ***p < 0.001 according to repeated measures ANOVA. Scale bar represents 100 μm. The expression of CD31 was scored as the percentage of positive tumor cells divided by the total number of tumor cells examined, which were analyzed by the Aperio ImageScope software v8.2.5. b The efficacy of apatinib monotherapy and combination with paclitaxel in two PDX models. NS, p > 0.05; *p < 0.05, ***p < 0.001 according to repeated measures ANOVA. c The efficacy of afatinib in four PDX models with different expression levels of EGFR and HER2. The proportion of tumor growth inhibition were expressed as means ± SD. NS, p > 0.05; ***p < 0.001 according to repeated measures ANOVA. d Afatinib induced tumor growth inhibition in EGFR-amplified (case 141), EGFR-overexpressed (case 078), and HER2-amplified (case 176) PDX models (n = 5 per group). Tumor volumes were expressed as means ± SD. NS, p > 0.05, ***p < 0.001 according to repeated measures ANOVA. CR, complete regression. Scale bar represents 100 μm